Prikap Side effects

How old is patient?
sponsored

What are the possible side effects of Prikap?

Get emergency medical help if you have signs of an allergic reaction to Prikap: hives; difficult breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have:

Some people taking Prikap have fallen asleep during normal daytime activities such as working, talking, eating, or driving. Tell your doctor if you have any problems with daytime sleepiness or drowsiness.

You may have increased sexual urges, unusual urges to gamble, or other intense urges while taking this medicine. Talk with your doctor if this occurs.

You may notice that your sweat, urine, or saliva appears dark in color, such as red, brown, or black. This is not a harmful side effect, but it may cause staining of your clothes or bed sheets.

Common Prikap side effects may include:

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Prikap side effects (more detail)

Side effects of Prikap in details

sponsored

The following serious adverse reactions are discussed below and elsewhere in the labeling:

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

The safety population consisted of a total of 978 Parkinson's disease patients who received at least one dose of Prikap, and had an average duration of exposure of 40 weeks.

Adverse Reactions In Early Parkinson's Disease

In a placebo-controlled clinical study in patients with early Parkinson's disease (Study 1), the most common adverse reactions with Prikap (in at least 5% of patients and more frequently than in placebo) were nausea, dizziness, headache, insomnia, abnormal dreams, dry mouth, dyskinesia, anxiety, constipation, vomiting, and orthostatic hypotension.

Table 2 lists adverse reactions occurring in at least 5% of Prikap-treated patients and at a higher rate than placebo in Study 1.

Table 2: Adverse Reactions in Study 1 in Patients with Early Stage Parkinson's Disease

Placebo Prikap 36.25 mg Carbidopa (Prikap)

145 mg Levodopa (Prikap) TID

Prikap 61.25 mg Carbidopa (Prikap)

245 mg Levodopa (Prikap) TID

Prikap 97.5 mg Carbidopa (Prikap)

390 mg Levodopa (Prikap) TID

(N=92)

%

(N=87)

%

(N=104)

%

(N=98)

%

Nausea 9 14 19 20
Dizziness 5 9 19 12
Headache 11 7 13 17
Insomnia 3 2 9 6
Abnormal Dreams 0 2 6 5
Dry Mouth 1 3 2 7
Dyskinesia 0 2 4 5
Anxiety 0 2 3 5
Constipation 1 2 6 2
Vomiting 3 2 2 5
Orthostatic
Hypotension 1 1 1 5

Adverse Reactions Leading to Discontinuation in Study 1

In Study 1, 12% of patients discontinued Prikap early due to adverse reactions; a higher proportion of patients in the 61.25 mg / 245 mg Prikap-treated group (14%) and in the 97.5 mg / 390 mg Prikap-treated group (15%) experienced adverse reactions leading to early discontinuation compared to (4%) in the placebo group. The most common adverse reactions resulting in early discontinuation were nausea, dizziness, and vomiting.

Adverse Reactions In Advanced Parkinson's Disease

In an active-controlled clinical study in patients with advanced Parkinson's disease (Study 2), the most common adverse reactions with Prikap that occurred during dose conversion or maintenance (in at least 5% of patients and more frequently than on oral immediate-release Carbidopa (Prikap)-Levodopa (Prikap)) were nausea and headache.

Table 3 lists adverse reactions occurring in at least 5% of Prikap-treated patients and at a higher rate than oral immediate-release Carbidopa (Prikap)-Levodopa (Prikap) in Study 2.

Table 3: Adverse Reactions in Study 2 in Patients with Advanced Parkinson's Disease

Period Prikap

(N=201)

Immediate-Release Carbidopa (Prikap)-Levodopa (Prikap)

(N=192)

Dose Convers ion* Maintenance Dose Convers ion* Maintenance
% % % %
Nausea 4 3 6 2
Headache 5 1 3 2
*All patients were converted to Prikap in the open label Dose Conversion period and then received randomized treatment during maintenance.

Adverse Reactions Leading to Discontinuation in Study 2

In Study 2, 5% of patients discontinued treatment due to adverse reactions during conversion to Prikap. The common adverse reactions leading to discontinuation during dose conversion were dyskinesia, anxiety, dizziness, and on and off phenomenon.

What is the most important information I should know about Prikap?

Prikap contraindications

sponsored

Nonselective monoamine oxidase (MAO) inhibitors are contraindicated for use with Prikap orally disintegrating tablets. These inhibitors must be discontinued at least two weeks prior to initiating therapy with Prikap orally disintegrating tablets. Prikap orally disintegrating tablets may be administered concomitantly with the manufacturer’s recommended dose of an MAO inhibitor with selectivity for MAO type B (e.g., selegiline HCI).

Prikap orally disintegrating tablets are contraindicated in patients with known hypersensitivity to any component of this drug, and in patients with narrow-angle glaucoma.

Because Levodopa (Prikap) may activate a malignant melanoma, Prikap orally disintegrating tablets should not be used in patients with suspicious, undiagnosed skin lesions or a history of melanoma.

References

  1. DailyMed. "CARBIDOPA; ENTACAPONE; LEVODOPA: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. DTP/NCI. "levodopa: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).
  3. DTP/NCI. "carbidopa: The NCI Development Therapeutics Program (DTP) provides services and resources to the academic and private-sector research communities worldwide to facilitate the discovery and development of new cancer therapeutic agents.". https://dtp.cancer.gov/dtpstandard/s... (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Prikap are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Prikap. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported side effects

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 15 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved